Trial · NCT03992131
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A1: Rucaparib 300 mg BID and Lucitanib 4 mg QD | 6 | |
| Overall Study | STARTED | Arm A2: Rucaparib 400 mg BID and Lucitanib 4 mg QD | 4 | |
| Overall Study | STARTED | Arm A3: Rucaparib 400 mg BID and Lucitanib 6 mg QD | 3 | |
| Overall Study | STARTED | Arm A4: Rucaparib 600 mg BID and Lucitanib 6 mg QD | 6 | |
| Overall Study | STARTED | Arm B1: Rucaparib 300 mg BID and Sacituzumab Govitecan | 3 | |
| Overall Study | STARTED | Arm B2: Rucaparib 300 mg QD and Sacituzumab Govitecan | 3 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Arm A1: Rucaparib 300 mg BID and Lucitanib 4 mg QD | 6 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Arm A2: Rucaparib 400 mg BID and Lucitanib 4 mg QD | 4 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Arm A3: Rucaparib 400 mg BID and Lucitanib 6 mg QD | 3 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Arm A4: Rucaparib 600 mg BID and Lucitanib 6 mg QD | 6 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Arm B1: Rucaparib 300 mg BID and Sacituzumab Govitecan | 3 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Arm B2: Rucaparib 300 mg QD and Sacituzumab Govitecan | 3 | |
| Overall Study | COMPLETED | Arm A1: Rucaparib 300 mg BID and Lucitanib 4 mg QD | 6 | |
| Overall Study | COMPLETED | Arm A2: Rucaparib 400 mg BID and Lucitanib 4 mg QD | 4 | |
| Overall Study | COMPLETED | Arm A3: Rucaparib 400 mg BID and Lucitanib 6 mg QD | 3 | |
| Overall Study | COMPLETED | Arm A4: Rucaparib 600 mg BID and Lucitanib 6 mg QD | 6 | |
| Overall Study | COMPLETED | Arm B1: Rucaparib 300 mg BID and Sacituzumab Govitecan | 3 | |
| Overall Study | COMPLETED | Arm B2: Rucaparib 300 mg QD and Sacituzumab Govitecan | 3 | |
| Overall Study | NOT COMPLETED | Arm A1: Rucaparib 300 mg BID and Lucitanib 4 mg QD | 0 | |
| Overall Study | NOT COMPLETED | Arm A2: Rucaparib 400 mg BID and Lucitanib 4 mg QD | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03992131/flow